Breaking News


A controlled study of topical tacrolimus in vitiligo


A 6-month, controlled, randomized, observer-blinded study assessed the effects of once-daily versus twice-daily topical tacrolimus ointment 0.1% in 17 patients (aged 10-61 years) with vitiligo. Two similar lesions in each patient were randomized to either once- or twice-daily treatment with tacrolimus ointment. In 10 patients, a third patch was left untreated to serve as a control. Repigmentation was graded as none (0%), poor (1-25%), moderate (26-50%), good (51-75%) or excellent (76-100%). Fifteen patients completed the study. Twice-daily therapy for 6 months produced some repigmentation in 10 of 15 (67%) lesions, while once-daily treatment did so in 7 of 15 (46%) of lesions. Moderate repigmentation only occurred in one untreated control lesions; the ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list